Innovation Spirits
We have independently developed 10 minimally invasive interventional treatment solutions targeting tricuspid valve diseases, mitral valve diseases, aortic valve diseases, and heart failure. All products are based on our original innovation and possess global patents and independent intellectual property rights.

MitraPatch, our proprietary TMVr system, is designed to treat patients with severe mitral regurgitations, especially those caused by leaflet prolapse. MitraPatch is made of bovine pericardium that is trimmed to size. MitraPatch is an innovative TMVr product candidate that can repair mitral valves using leaflet patching technologies.